Form 4: Charles River Laboratories CFO Flavia Pease Reports Grant of Restricted Stock Units and Tax-Related Disposition

Charles River Laboratories' Corporate Executive VP & CFO, Flavia Pease, reported the acquisition of 7,152 restricted stock units and a subsequent disposition of 185 shares for tax withholding purposes.

Summary

• Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories International, Inc. (CRL), reported transactions involving the company's common stock.
• On May 30, 2025, Ms. Pease acquired 7,152 shares of common stock at a price of $135.63 per share, representing unvested restricted stock units.
• These restricted stock units are scheduled to vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.
• Following this acquisition, Ms. Pease's beneficial ownership increased to 17,482 shares.
• On May 31, 2025, Ms. Pease disposed of 185 shares of common stock at the same price of $135.63 per share, which was for the payment of tax liability.
• After the disposition, Ms. Pease's beneficial ownership stands at 17,297 shares.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive sign of long-term incentive alignment and retention. The subsequent disposition for tax purposes is a routine event and does not detract significantly from the overall positive sentiment of the equity grant.

Positives

• The grant of 7,152 restricted stock units to a key executive like the CFO aligns her interests with long-term shareholder value.
• The vesting schedule over four years (2026-2029) indicates a commitment to retaining key talent and incentivizing long-term performance.

Negatives

• The disposition of 185 shares, while for tax purposes, slightly reduces the direct beneficial ownership immediately following the grant.

Future Outlook

The vesting schedule for the restricted stock units provides a clear timeline for future share grants to the CFO, extending through May 2029.

Industry Context

This filing is a routine disclosure of executive compensation in the form of equity, common across publicly traded companies in all industries, including the life sciences and research services sector where Charles River Laboratories operates. It reflects standard practices for aligning executive incentives with shareholder interests.

Comparison to Industry Standards

• This Form 4 filing details a standard executive compensation practice involving restricted stock units and subsequent tax-related dispositions, which is common across publicly traded companies. Specific comparable companies or projects are not detailed in this filing, as it focuses on an individual's transactions rather than company-wide performance or strategic initiatives.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO aligns her interests with shareholders, potentially encouraging long-term performance and value creation.
• Employees: This reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The restricted stock units will vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.

Key Dates

Recommendation

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Flavia Pease, Stock Grant, Tax Withholding, Corporate Officer